gst-hg171
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Oct 2, 2022 (NCT05668897)
Timeline
Indications
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06087055 | Phase 1 | May 12, 2023 | Government of China |
| NCT06084507 | Phase 1 | May 4, 2023 | Government of China |
| NCT06106126 | N/A | Feb 10, 2023 | Government of China |
| NCT05656443 | Phase 2/Phase 3 (Phase 3) | Dec 22, 2022 | Government of China |
| NCT06106113 | Phase 1 | Dec 15, 2022 | Government of China |
| NCT05668897 | Phase 1 | Oct 2, 2022 | Government of China |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 6 | 6 | 3 | 2022 |
1 organizations
Page 1 / 1